These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23747209)

  • 1. Valproate as a risk factor for lamotrigine discontinuation.
    Abe Y; Yasugawa S; Miyamoto K; Terao T
    J Affect Disord; 2013 Sep; 150(3):1197-9. PubMed ID: 23747209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open study of lamotrigine in refractory bipolar depression.
    Kusumakar V; Yatham LN
    Psychiatry Res; 1997 Sep; 72(2):145-8. PubMed ID: 9335206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lamotrigine in the treatment of mental disorders].
    Malt UF; Fladvad T
    Tidsskr Nor Laegeforen; 2001 May; 121(12):1473-7. PubMed ID: 11449770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder.
    Chang CC; Shiah IS; Chang HA; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):147-50. PubMed ID: 16225978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate.
    Hashim N; Bandara D; Tan E; Ilchyshyn A
    Acta Derm Venereol; 2004; 84(1):90-1. PubMed ID: 15040495
    [No Abstract]   [Full Text] [Related]  

  • 7. [Secondary delirium due to the use of lamotrigine with abrupt increase valproic acid's dose].
    Rocha FF
    Braz J Psychiatry; 2008 Mar; 30(1):88. PubMed ID: 18373026
    [No Abstract]   [Full Text] [Related]  

  • 8. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk.
    Li LM; Russo M; O'Donoghue MF; Duncan JS; Sander JW
    Arq Neuropsiquiatr; 1996 Mar; 54(1):47-9. PubMed ID: 8736144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.
    Burneo JG; Limdi N; Kuzniecky RI; Knowlton RC; Mendez M; Lawn N; Faught E; Welty TE; Prasad A
    Neurology; 2003 Jun; 60(12):1991-2. PubMed ID: 12821749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
    Yatham LN; Kennedy SH; O'Donovan C; Parikh S; MacQueen G; McIntyre R; Sharma V; Silverstone P; Alda M; Baruch P; Beaulieu S; Daigneault A; Milev R; Young LT; Ravindran A; Schaffer A; Connolly M; Gorman CP;
    Bipolar Disord; 2005; 7 Suppl 3():5-69. PubMed ID: 15952957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder.
    Chang CC; Shiah IS; Yeh CB; Wang TS; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):741-4. PubMed ID: 16442685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamotrigine augmentation strategy for patients with treatment-resistant depression.
    Gutierrez RL; McKercher RM; Galea J; Jamison KL
    CNS Spectr; 2005 Oct; 10(10):800-5. PubMed ID: 16400242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy.
    Sale ME; Natarajan S; Biton V; Vuong A; Hammer AE; Messenheimer JA; Blum D
    Epilepsy Behav; 2005 Feb; 6(1):63-70. PubMed ID: 15652736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticonvulsants (carbamazepine, valproate, lamotrigine) in bipolar affective disorder].
    Puzyński S
    Psychiatr Pol; 2002; 36(6 Suppl):53-61. PubMed ID: 12647422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional interaction of valproate and lamotrigine in healthy subjects.
    Anderson GD; Yau MK; Gidal BE; Harris SJ; Levy RH; Lai AA; Wolf KB; Wargin WA; Dren AT
    Clin Pharmacol Ther; 1996 Aug; 60(2):145-56. PubMed ID: 8823232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability.
    Leunissen CL; de la Parra NM; Tan IY; Rentmeester TW; Vader CI; Veendrick-Meekes MJ; Aldenkamp AP
    Res Dev Disabil; 2011; 32(6):2660-8. PubMed ID: 21752594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late adverse effects of the coadministration of valproate and lamotrigine.
    Thome-Souza S; Moreira B; Valente KD
    Pediatr Neurol; 2012 Jul; 47(1):47-50. PubMed ID: 22704017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro.
    Schaub N; Bircher AJ
    Allergy; 2000 Feb; 55(2):191-3. PubMed ID: 10726736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid.
    Yalçin B; Karaduman A
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):898-9. PubMed ID: 11044815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study.
    Kikkawa A; Kitamura Y; Aiba T; Hiraki K; Sendo T
    Biol Pharm Bull; 2017; 40(4):413-418. PubMed ID: 28381796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.